Specifically, we demonstrated that high RPA3 expression contributed to the radioresistance of NPC and that RPA3 has the potential to be a biomarker that predicts prognosis and radiosensitivity for patients with NPC. This evidence concerns the gene RPA3 and nasopharyngeal carcinoma.